According to the Complaint, DexCom, Inc. is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. DexCom’s G7 continuous glucose monitoring system, designed and distributed as an upgrade over the prior G6 model, was launched in early 2023.

During the Class Period, Defendants provided investors with material information concerning DexCom’s expected revenue for the fiscal year 2024. Defendants’ statements included, among other things, confidence in the DexCom’s ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year’s gross margins, while scaling customer conversion to the new G7 platform.

The Complaint alleges that during the Class Period, Defendants failed to disclose the true state of DexCom’s salesforce; notably, that it was not truly equipped to execute on the Company’s perceived growth potential, and that as a result of their purchases of DexCom’s common stock during the Class Period, Plaintiff and other members of the Class suffered economic loss.

On December 13, 2024, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. All future docketing was ordered to be done in the lead case 24-CV-01485.

Lead Plaintiff filed a Consolidated Complaint on January 27, 2025. Defendants filed a Motion to Dismiss the Consolidated Complaint on March 13. On May 14, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiff was given leave to amend the Complaint.

On May 28, 2025, Lead Plaintiff filed an Amended Consolidated Complaint.